Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach

• Published in: Chemico-biological interactions 2023-03, Vol.373, p.110400-110400, Article 110400
• Main Authors: Pan, Chunyang, Cheng, Yifan, He, Qingfeng, Li, Min, Bu, Fengjiao, Zhu, Xiao, Li, Xiaoyu, Xiang, Xiaoqiang
• Format: Article
• Language: English
• Subjects: Drug-drug interaction (DDI); Gastrointestinal stromal tumor (GIST); Physiologically-based pharmacokinetic (PBPK) model; Ripretinib
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2023.110400

Ripretinib, as an oral kinase inhibitor, has been approved to treat advanced gastrointestinal stromal tumors (GIST) and is often used in combination with other drugs to slow disease progression, thus potential drug-drug Interactions (DDIs) and drug-disease interactions (DDZIs) have received much attention. To guide clinical rational drug use, this study assessed the effect of co-administered drugs and diseases on ripretinib exposure. Simcyp® Simulator was used to develop the physiologically-based pharmacokinetic (PBPK) model of ripretinib, which was validated and refined with clinical data. We then examined the impact of several CYP3A4 inhibitors and inducers as well as different diseases on ripretinib exposure using the validated model. In the DDI simulation, moderate CYP3A4 inhibitors and inducers changed the exposure of ripretinib by 1.25–2 fold. In hepatic impairment (HI), the simulation showed that ripretinib's AUC increased by 32%, 100%, and 152% for Child-Pugh A, B, and C classification while Cmax increased by 2%, 10%, and 15%, respectively. In renal impairment (RI), the model-simulated AUC in moderate and severe RIs increased by 27% and 20%. In conclusion, PBPK models demonstrated quantitative prediction of ripretinib's pharmacokinetic changes under varying conditions that might be useful for its rational use. •Moderate to severe renal impairment (RI) and hepatic impairment (HI) have little effect on ripretinib exposure.•Concomitant use of ripretinib and strong CYP3A inducers resulted in reduced ripretinib exposure.•This work utilizes PBPKs to provide drug-drug interaction (DDI) insights for populations treated with ripretinib.